CN
Home
About Us
News
R&D innovation
Back
Biopharmaceuticals
Functional ingredients
Nutritional products
Product Center
Back
Biopharmaceuticals
Functional ingredients
Nutritional products
Internationalization
Development
Back
2023/ 12/02
【媒体报道】超300%增长，今年最强医药股凭什么？
< Previous Article：
巨石生物签署关于登革热mRNA疫苗研发协议
Next Article：
石药创新新冠病毒二价mRNA疫苗被纳入紧急使用
Related News
2026/09/15
CSPC Innovation’s SYS6010 Presents Research Findings at the 2026 World Conference on Lung Cancer (WCLC)
2026/08/13
CSPC Innovation’s Subsidiary Receives Upfront Payment under the Cooperation, Option and Licence Agreement with AstraZeneca
2026/08/04
CSPC Innovation’s SYS6090 Initiates Phase Ib/II Clinical Trial
2026/06/27
CSPC Innovation Initiates Phase III Clinical Trial of SYS6010
News
